$ISCO
International Stem Cell CORP

2023 Q2 Form 10-Q Financial Statement

#000095017023021741 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $1.841M $2.086M $2.430M
YoY Change -9.18% 3.27% 31.85%
Cost Of Revenue $713.0K $824.0K $1.136M
YoY Change -0.7% 13.66% 54.56%
Gross Profit $1.128M $1.262M $1.294M
YoY Change -13.83% -2.55% 16.79%
Gross Profit Margin 61.27% 60.5% 53.25%
Selling, General & Admin $1.227M $1.115M $1.108M
YoY Change 2.68% -1.59% -9.77%
% of Gross Profit 108.78% 88.35% 85.63%
Research & Development $45.00K $145.0K $125.0K
YoY Change -45.78% 5.84% -38.42%
% of Gross Profit 3.99% 11.49% 9.66%
Depreciation & Amortization $48.00K $51.00K $52.00K
YoY Change -12.73% -8.93% -22.39%
% of Gross Profit 4.26% 4.04% 4.02%
Operating Expenses $1.272M $1.260M $1.233M
YoY Change -0.47% 11.21% -13.84%
Operating Profit -$144.0K $2.000K $61.00K
YoY Change -564.52% -92.0% -118.89%
Interest Expense $35.00K $36.00K -$33.00K
YoY Change -206.06% -205.88% -19.51%
% of Operating Profit 1800.0% -54.1%
Other Income/Expense, Net $636.0K -$36.00K -$5.000K
YoY Change -2027.27% -205.88% -138.46%
Pretax Income $492.0K -$34.00K $23.00K
YoY Change -24700.0% 277.78% -106.55%
Income Tax
% Of Pretax Income
Net Earnings $492.0K -$34.00K $23.00K
YoY Change -24700.0% 277.78% -106.55%
Net Earnings / Revenue 26.72% -1.63% 0.95%
Basic Earnings Per Share $0.03 $0.00
Diluted Earnings Per Share $0.03 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 8.004M 8.004M 8.004M
Diluted Shares Outstanding 8.004M 8.004M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.382M $943.0K $742.0K
YoY Change 135.84% 136.93% 333.92%
Cash & Equivalents $1.382M $943.0K $742.0K
Short-Term Investments
Other Short-Term Assets $32.00K $26.00K $90.00K
YoY Change -49.21% -92.31% 429.41%
Inventory $1.296M $1.294M $1.384M
Prepaid Expenses $213.0K $285.0K $64.00K
Receivables $662.0K $688.0K $747.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.684M $3.236M $2.963M
YoY Change 23.05% 9.32% 26.95%
LONG-TERM ASSETS
Property, Plant & Equipment $256.0K $232.0K $248.0K
YoY Change -18.21% -33.33% -35.42%
Goodwill
YoY Change
Intangibles $837.0K $858.0K $878.0K
YoY Change -8.72% -7.48%
Long-Term Investments
YoY Change
Other Assets $363.0K $328.0K $319.0K
YoY Change -7.4% -22.82% -22.38%
Total Long-Term Assets $2.102M $2.105M $2.172M
YoY Change -13.21% -17.16% -16.85%
TOTAL ASSETS
Total Short-Term Assets $3.684M $3.236M $2.963M
Total Long-Term Assets $2.102M $2.105M $2.172M
Total Assets $5.786M $5.341M $5.135M
YoY Change 6.83% -2.91% 3.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $331.0K $351.0K $322.0K
YoY Change -30.61% -44.72% -36.61%
Accrued Expenses $521.0K $632.0K $508.0K
YoY Change 3.99% -9.84% 25.74%
Deferred Revenue
YoY Change
Short-Term Debt $3.390M $3.357M $3.325M
YoY Change 4.05% 4.09% 12.98%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.744M $4.831M $4.635M
YoY Change 1.07% 0.42% 8.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $588.0K $656.0K $720.0K
YoY Change -30.0% -26.79% -24.21%
Total Long-Term Liabilities $588.0K $656.0K $720.0K
YoY Change -30.0% -26.79% -24.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.744M $4.831M $4.635M
Total Long-Term Liabilities $588.0K $656.0K $720.0K
Total Liabilities $5.332M $5.487M $5.355M
YoY Change -3.65% -3.85% 2.31%
SHAREHOLDERS EQUITY
Retained Earnings -$109.9M -$110.4M -$110.3M
YoY Change -0.09% 0.36% 0.26%
Common Stock $8.000K $8.000K $8.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.846M -$4.446M -$4.520M
YoY Change
Total Liabilities & Shareholders Equity $5.786M $5.341M $5.135M
YoY Change 6.83% -2.91% 3.82%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income $492.0K -$34.00K $23.00K
YoY Change -24700.0% 277.78% -106.55%
Depreciation, Depletion And Amortization $48.00K $51.00K $52.00K
YoY Change -12.73% -8.93% -22.39%
Cash From Operating Activities $490.0K $216.0K $79.00K
YoY Change 155.21% -1039.13% -125.0%
INVESTING ACTIVITIES
Capital Expenditures $51.00K $15.00K $3.000K
YoY Change -1375.0% -116.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$51.00K -$15.00K -$3.000K
YoY Change 1175.0% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 490.0K 216.0K 79.00K
Cash From Investing Activities -51.00K -15.00K -3.000K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash 439.0K 201.0K 76.00K
YoY Change 133.51% -19.6% -122.75%
FREE CASH FLOW
Cash From Operating Activities $490.0K $216.0K $79.00K
Capital Expenditures $51.00K $15.00K $3.000K
Free Cash Flow $439.0K $201.0K $76.00K
YoY Change 123.98% -973.91% -125.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001355790
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-51891
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
INTERNATIONAL STEM CELL CORPORATION
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4494098
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9745 Businesspark Ave
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
CY2023Q1 dei City Area Code
CityAreaCode
760
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
940-6383
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8004389
CY2023Q1 us-gaap Cash
Cash
943000
CY2022Q4 us-gaap Cash
Cash
742000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
688000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2023Q1 us-gaap Inventory Net
InventoryNet
1294000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
3236000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2963000
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
295000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
232000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
858000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
878000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
687000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
727000
CY2023Q1 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2022Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2023Q1 us-gaap Assets
Assets
5341000
CY2022Q4 us-gaap Assets
Assets
5135000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
351000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
322000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
632000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
508000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
241000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230000
CY2023Q1 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2022Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2023Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
3357000
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
3325000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4831000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4635000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
656000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
720000
CY2023Q1 us-gaap Liabilities
Liabilities
5487000
CY2022Q4 us-gaap Liabilities
Liabilities
5355000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105920000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105812000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110379000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110345000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4446000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5341000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5135000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2086000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2020000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
824000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
725000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
800000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
832000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
315000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
301000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
145000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
137000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2084000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1995000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
25000
CY2023Q1 us-gaap Interest Expense
InterestExpense
36000
CY2022Q1 us-gaap Interest Expense
InterestExpense
34000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4446000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-4588000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4506000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-9000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56000
CY2023Q1 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
40000
CY2022Q1 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
33000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
108000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91000
CY2023Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
32000
CY2022Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
32000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
58000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-81000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
156000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
221000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
203000
CY2022Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
29000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
125000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
124000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
99000
CY2023Q1 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-53000
CY2022Q1 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-37000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
216000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
250000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
201000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
227000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
742000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
943000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
398000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110400000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</span></p>
CY2023Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1589000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2023Q1 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The anti-aging market sells products solely through the ecommerce channel. The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three months ended March 31, 2023 and 2022.
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q1 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
688000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2307000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
668000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
637000
CY2023Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1589000
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2023Q1 us-gaap Inventory Net
InventoryNet
1294000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
295000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12935014
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11449057
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentrations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of consolidated revenues, respectively. As of March 31, 2023 and December 31, 2022, the customer accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
579000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
615000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
557000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
498000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1121000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1194000
CY2023Q1 us-gaap Inventory Gross
InventoryGross
2257000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
285000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
64000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2478000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2467000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2246000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2219000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
232000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
37000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
119000
CY2023Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1286000
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1286000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
503000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
483000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
783000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
803000
CY2023Q1 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2022Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
858000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
878000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2023Q1 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
349000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
360000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
108000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
522000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M21D
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15609580
CY2021Q4 isco Lease Costs Incurred Percentage
LeaseCostsIncurredPercentage
0.40
CY2023Q1 isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
11000
CY2021Q4 isco Percentage Of Increase Rent Per Annum Over Lease Term
PercentageOfIncreaseRentPerAnnumOverLeaseTerm
0.035
CY2021Q4 isco Percentage Of Base Rent Abated
PercentageOfBaseRentAbated
0.50
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
71000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
73000
CY2023Q1 isco Finance Leases
FinanceLeases
0
CY2022Q4 isco Finance Leases
FinanceLeases
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
254000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1082000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
185000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
897000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
241000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
656000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2086000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2020000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2084000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1995000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
25000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
isco-20230331_lab.xml Edgar Link unprocessable
0000950170-23-021741-index-headers.html Edgar Link pending
0000950170-23-021741-index.html Edgar Link pending
0000950170-23-021741.txt Edgar Link pending
0000950170-23-021741-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
isco-20230331.htm Edgar Link pending
isco-20230331.xsd Edgar Link pending
isco-20230331_cal.xml Edgar Link unprocessable
isco-20230331_def.xml Edgar Link unprocessable
isco-20230331_htm.xml Edgar Link completed
isco-ex31_1.htm Edgar Link pending
isco-ex31_2.htm Edgar Link pending
isco-ex32_1.htm Edgar Link pending
isco-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
isco-20230331_pre.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending